Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases. 

Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.

Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s Covid-19 vaccine, raised $168 million in a Series B financing round that will be used to support development of its own lead candidates in oncology and infectious disease.

Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.

LightDeck Diagnostics was awarded a $5.65 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services (HHS), to develop an rapid antigen test to detect SARS-CoV-2.

Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.

BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

Thrive Earlier Detection, headquartered in Cambridge, Massachusetts, closed on a Series B financing worth $257 million.

Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.